Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP9 | P14780 | 6/20 | 0.46 |
| ▸ | MMP2 | P08253 | 6/20 | 0.46 |
| ▸ | MMP1 | P03956 | 6/20 | 0.46 |
| ▸ | MMP3 | P08254 | 2/20 | 0.46 |
| ▸ | MMP14 | P50281 | 1/20 | 0.46 |
| ▸ | MMP8 | P22894 | 4/20 | 0.45 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | FCER2 | P06734 | 1/20 | 0.41 |
| ▸ | ANPEP | P15144 | 2/20 | 0.41 |
| ▸ | CTSS | P25774 | 1/20 | 0.40 |
| ▸ | CTSK | P43235 | 1/20 | 0.40 |
| ▸ | MME | P08473 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5552388 | 0.92 | MMP9 (0.58) | MMP9MMP2MMP1MMP3MMP14 | |
| SCHEMBL5556562 | 0.85 | MMP9 (0.60) | MMP9MMP2MMP1MMP3MMP14 | |
| SCHEMBL5556556 | 0.85 | MMP9 (0.60) | MMP9MMP2MMP1MMP3MMP14 | |
| SCHEMBL5552424 | 0.84 | ANPEP (0.53) | MMP9MMP2MMP1MMP3MMP8 | |
| SCHEMBL5552841 | 0.81 | MMP9 (0.56) | MMP9MMP2MMP1MMP3MMP14 | |
| SCHEMBL5552883 | 0.80 | GPR88 (0.52) | MMP9MMP2MMP1MMP3MMP14 | |
| SCHEMBL5556423 | 0.79 | MMP9 (0.52) | MMP9MMP2MMP1MMP3MMP14 | |
| SCHEMBL5557472 | 0.79 | MMP9 (0.52) | MMP9MMP2MMP1MMP3MMP14 | |
| SCHEMBL5558416 | 0.78 | MMP9 (0.55) | MMP9MMP2MMP1MMP3MMP14 | |
| SCHEMBL5558413 | 0.78 | MMP9 (0.55) | MMP9MMP2MMP1MMP3MMP14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070197577-A1 | Inhibitors of anthrax lethal factor | CENGENT THERAPEUTICS (US) | 2007-08-23 | — | — | US | disclosed |
| WO-2005027856-A2 | INHIBITORS OF ANTHRAX LETHAL FACTOR | CENGENT THERAPEUTICS (US) | 2005-03-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070197577-A1 | Inhibitors of anthrax lethal factor | APAF1, ANTXR2, LITAF | MMP9 182/4885MMP2 85/4885MMP1 950/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.